|
ATCC
hap1 ifitm3 knockout ![]() Hap1 Ifitm3 Knockout, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/hap1 ifitm3 knockout/product/ATCC Average 93 stars, based on 1 article reviews
hap1 ifitm3 knockout - by Bioz Stars,
2026-03
93/100 stars
|
Buy from Supplier |
|
Thermo Fisher
gene exp ifitm1 hs00705137 s1 ![]() Gene Exp Ifitm1 Hs00705137 S1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/gene exp ifitm1 hs00705137 s1/product/Thermo Fisher Average 92 stars, based on 1 article reviews
gene exp ifitm1 hs00705137 s1 - by Bioz Stars,
2026-03
92/100 stars
|
Buy from Supplier |
|
OriGene
mifitm1 origene cat ![]() Mifitm1 Origene Cat, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/mifitm1 origene cat/product/OriGene Average 92 stars, based on 1 article reviews
mifitm1 origene cat - by Bioz Stars,
2026-03
92/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
primary antibodies against ifitm1 ![]() Primary Antibodies Against Ifitm1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/primary antibodies against ifitm1/product/Cell Signaling Technology Inc Average 94 stars, based on 1 article reviews
primary antibodies against ifitm1 - by Bioz Stars,
2026-03
94/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
mouse monoclonal anti ifitm1 2 3 ![]() Mouse Monoclonal Anti Ifitm1 2 3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/mouse monoclonal anti ifitm1 2 3/product/Santa Cruz Biotechnology Average 93 stars, based on 1 article reviews
mouse monoclonal anti ifitm1 2 3 - by Bioz Stars,
2026-03
93/100 stars
|
Buy from Supplier |
|
Proteintech
anti ifitm1 ![]() Anti Ifitm1, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/anti ifitm1/product/Proteintech Average 94 stars, based on 1 article reviews
anti ifitm1 - by Bioz Stars,
2026-03
94/100 stars
|
Buy from Supplier |
|
Proteintech
ifitm1 ![]() Ifitm1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/ifitm1/product/Proteintech Average 93 stars, based on 1 article reviews
ifitm1 - by Bioz Stars,
2026-03
93/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
ifitm1 crispr cas9 hdr plasmids ![]() Ifitm1 Crispr Cas9 Hdr Plasmids, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/ifitm1 crispr cas9 hdr plasmids/product/Santa Cruz Biotechnology Average 92 stars, based on 1 article reviews
ifitm1 crispr cas9 hdr plasmids - by Bioz Stars,
2026-03
92/100 stars
|
Buy from Supplier |
|
Thermo Fisher
gene exp ifitm1 hs01652522 g1 ![]() Gene Exp Ifitm1 Hs01652522 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/gene exp ifitm1 hs01652522 g1/product/Thermo Fisher Average 92 stars, based on 1 article reviews
gene exp ifitm1 hs01652522 g1 - by Bioz Stars,
2026-03
92/100 stars
|
Buy from Supplier |
|
Novus Biologicals
transmembrane 1 ifitm1 ![]() Transmembrane 1 Ifitm1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/transmembrane 1 ifitm1/product/Novus Biologicals Average 92 stars, based on 1 article reviews
transmembrane 1 ifitm1 - by Bioz Stars,
2026-03
92/100 stars
|
Buy from Supplier |
|
Thermo Fisher
gene exp ifitm1 mm00850040 g1 ![]() Gene Exp Ifitm1 Mm00850040 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/gene exp ifitm1 mm00850040 g1/product/Thermo Fisher Average 85 stars, based on 1 article reviews
gene exp ifitm1 mm00850040 g1 - by Bioz Stars,
2026-03
85/100 stars
|
Buy from Supplier |
|
Boster Bio
pa1112 ![]() Pa1112, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/pa1112/product/Boster Bio Average 90 stars, based on 1 article reviews
pa1112 - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: bioRxiv
Article Title: Innate immune control of influenza virus interspecies adaptation
doi: 10.1101/2023.08.23.554491
Figure Lengend Snippet: WT and Ifitm3 -/- mice were intranasally infected with ( a, b ) 1, 10, or 50 TCID50 of H5N1 avian influenza strain (2 independent experiments for doses 1 and 10 (n=10 mice) and 1 experiment for dose of 50 (n=5 mice)) or with ( c, d ) 1 or 10 TCID50 of H7N3 avian influenza strain (n=5 mice). a , c Viral titers from lung homogenates at day 3 post infection. b, d ELISA quantification of IL-6 levels in lung homogenates at day 3 post infection. a-d Error bars represent SEM. Comparisons were analyzed by ANOVA followed by Tukey’s multiple comparisons test. Only comparisons between WT and Ifitm3 -/- mice for each dose are shown.
Article Snippet: HeLa IFITM1/2/3 knockout and
Techniques: Infection, Enzyme-linked Immunosorbent Assay
Journal: bioRxiv
Article Title: Innate immune control of influenza virus interspecies adaptation
doi: 10.1101/2023.08.23.554491
Figure Lengend Snippet: ( a ) Schematic of in vitro infection with potentially zoonotic influenza viruses and representative example from infected A549 human lung cells. ( b ) The indicated A549 cells or THP-1 differentiated macrophages were treated +/- IFNβ for 18 hours, followed by infection with indicated viruses (MOI 1) for 24 hours. Percent infection was determined by flow cytometry and normalized to respective shControl or WT cells without IFNβ pre-treatment. Error bars represent SEM. P values are for the indicated comparisons and were determined by ANOVA followed by Tukey’s multiple comparisons test. Only statistical comparisons between shControl versus shIFITM3 and WT versus IFITM3 -/- are shown. Data are representative of 3 independent experiments each performed in triplicate (n=9). ( c, d ) Western blots of cell lysates at 18 hours +/- IFNβ treatment. Note that commercial IFITM3 antibodies weakly detect IFITM2 in addition to IFITM3. ( e ) The indicated A549 cells were infected with indicated viruses at a range of 0.001 to 10 MOI for 24 hours. Percent infection was determined by flow cytometry. Data are representative of 3 independent experiments each performed in triplicate (n=9). Error bars represent SEM. Comparisons were analyzed by ANOVA followed by Tukey’s multiple comparisons test. Only comparisons between control and knockdown cells are shown at each dose.
Article Snippet: HeLa IFITM1/2/3 knockout and
Techniques: In Vitro, Infection, Flow Cytometry, Western Blot, Control, Knockdown
Journal: bioRxiv
Article Title: Innate immune control of influenza virus interspecies adaptation
doi: 10.1101/2023.08.23.554491
Figure Lengend Snippet: HAP1 cells were treated +/- IFNβ for 18 hours, followed by infection with indicated viruses (MOI 1) for 24 hours. ( a ) Percent infection was determined by flow cytometry and normalized to results for WT cells without IFNβ pre-treatment. Error bars represent SEM. P values are for the indicated comparisons and were determined by ANOVA followed by Tukey’s multiple comparisons test. Only statistical comparisons between WT versus IFITM3 -/- are shown. Data are representative of 3 independent experiments each performed in triplicate (n=9). ( b ) Western blots of cell lysates at 18 hours +/- IFNβ treatment. ( c ) Example raw flow cytometry data for determination of normalized infection of WT and IFITM3 -/- HAP1 cells +/- IFNb treatment with each of the indicated virus strains as in ( a ). SSC, side scatter; Anti-influenza nucleoprotein antibody was detected in the APC channel with secondary antibody labeled with Alexafluor 647.
Article Snippet: HeLa IFITM1/2/3 knockout and
Techniques: Infection, Flow Cytometry, Western Blot, Virus, Labeling
Journal: bioRxiv
Article Title: Innate immune control of influenza virus interspecies adaptation
doi: 10.1101/2023.08.23.554491
Figure Lengend Snippet: HeLa cells were treated +/- IFNβ for 18 hours, followed by infection with indicated viruses (MOI 1) for 24 hours. ( a ) Percent infection was determined by flow cytometry and normalized to results for WT cells without IFNβ pre-treatment. Error bars represent SEM. P values are for the indicated comparisons and were determined by ANOVA followed by Tukey’s multiple comparisons test. Only statistical comparisons between WT versus IFITM3 -/- are shown. Data are representative of 3 independent experiments each performed in triplicate (n=9). ( b ) Western blots of cell lysates at 18 hours +/- IFNβ treatment. ( c ) Example raw flow cytometry data for determination of normalized infection of WT and IFITM1/2/3 -/- HeLa cells +/- IFNb treatment with each of the indicated virus strains as in a . SSC, side scatter; Anti-influenza nucleoprotein antibody was detected in the APC channel with secondary antibody labeled with Alexafluor 647.
Article Snippet: HeLa IFITM1/2/3 knockout and
Techniques: Infection, Flow Cytometry, Western Blot, Virus, Labeling
Journal: bioRxiv
Article Title: Innate immune control of influenza virus interspecies adaptation
doi: 10.1101/2023.08.23.554491
Figure Lengend Snippet: ( a ) Schematic of mouse passaging experiments. Initial intranasal infections were performed with 1,000 TCID50 of parental viruses. ( b ) Schematic of WT mouse challenge with parental or passaged viruses. ( c-h and j-l ) Groups of WT mice were challenged with equal doses of virus passaged 1, 5, or 10 times through WT or Ifitm3 -/- mice and compared to the parent virus (passage 0). ( c, e ) Viral titers from lung homogenates taken at day 7 ( c represents 2 independent experiments). Error bars represent SD of the mean. Comparisons were analyzed by ANOVA followed by Tukey’s post hoc test. ( d, f ) ELISA quantification of IL-6 levels in lung homogenates of WT and IFITM3 KO mice at day 7 post infection ( d represents 2 independent experiments). Error bars represent SD of the mean. Comparisons were analyzed by ANOVA followed by Tukey’s multiple comparisons test. ( g, j ) Viral titers from lung homogenates taken at day 7 ( g ) or day 6 ( j ) post infection. Error bars represent SD of the mean. Comparisons were analyzed by ANOVA followed by Tukey’s post hoc test. ( h, k ) ELISA quantification of IL-6 levels in lung homogenates of WT and IFITM3 KO mice at day 7 ( h ) or day 6 ( k ) post infection. Error bars represent SD of the mean. Comparisons were analyzed by ANOVA followed by Tukey’s multiple comparisons test. ( i, m ) Mutations found in the segments of A/California/04/2009 (H1N1) after serial passage through WT or Ifitm3 -/- mice. ( l ) Weight loss. Skull and crossbones indicate humane euthanasia of all animals infected with KO passage 10. Error bars represent SD of the mean, comparisons were made using the Mann-Whitney test (* P = 0.0022, ** P < 0.0001).
Article Snippet: HeLa IFITM1/2/3 knockout and
Techniques: Passaging, Virus, Enzyme-linked Immunosorbent Assay, Infection, MANN-WHITNEY
Journal: bioRxiv
Article Title: Innate immune control of influenza virus interspecies adaptation
doi: 10.1101/2023.08.23.554491
Figure Lengend Snippet: ( a ) Schematic of mouse passaging experiments. Initial intranasal infections were performed with 1,000 TCID50 of parental viruses. ( b ) Schematic of WT mouse challenge with parental or passaged viruses. ( c,d ) Groups of WT mice were challenged with equal doses of virus passaged 1, 5, or 10 times through WT or Stat1 -/- mice and compared to the parent virus (passage 0). ( c ) Viral titers from lung homogenates taken at day 7 post infection. Error bars represent SEM. Comparisons were analyzed by ANOVA followed by Tukey’s multiple comparisons test. ( d ) ELISA quantification of IL-6 levels in lung homogenates of WT and IFITM3 KO mice at day 7 post infection. Error bars represent SEM. Comparisons were analyzed by ANOVA followed by Tukey’s multiple comparisons test.
Article Snippet: HeLa IFITM1/2/3 knockout and
Techniques: Passaging, Virus, Infection, Enzyme-linked Immunosorbent Assay
Journal: Journal of Virology
Article Title: SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells
doi: 10.1128/jvi.00594-22
Figure Lengend Snippet: Impact of IFITMs on replication of the Omicron VOC. (A) Schematic presentation of amino acid variations in Spike proteins of the SARS-CoV-2 Delta and Omicron VOCs investigated. Abbreviations are defined in the legend to . (B) Viral N RNA levels in the supernatant of Calu-3 cells infected with the indicated SARS-CoV-2 variants. Cells were transfected with control or IFITM-targeting siRNAs as indicated. Numbers above the bars indicate n -fold reduction compared to the viral RNA levels detected in the supernatant of Calu-3 cells treated with control siRNA. Bars in panels B and C show the mean of 3 independent experiments (±SEM), each measured in technical duplicates. (C) Quantification of intracellular viral N RNA levels in Calu-3 cells 24 h postinfection with SARS-CoV-2 (MOI of 0.05). Values were normalized to GAPDH and calculated relative to the control (set to 100%). Cells were transiently transfected with siRNA—either control (CTRL) or targeting IFITM1, -2, or -3. (D) Exemplary Western blot of IFITM and viral N protein expression in Calu-3 cells treated with control or IFITM1-, -2-, and/or -3-targeting siRNA and infected with the indicated SARS-CoV-2 variants. GAPDH was detected as a loading control. P values: *, <0.05; **, <0.01; ****, <0.0001.
Article Snippet: Proteins were stained at 1:1,000 using
Techniques: Infection, Transfection, Control, Western Blot, Expressing
Journal: Journal of Virology
Article Title: SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells
doi: 10.1128/jvi.00594-22
Figure Lengend Snippet: Expression of ACE2 and IFITM proteins in Calu-3 and iATII cells. (A) Immunoblot of ACE2, IFITM1, IFITM2, and IFITM3 in Calu-3 and iATII cells left uninfected (lanes C) or infected with the indicated SARS-CoV-2 variants. Whole-cell lysates were stained with the indicated antibodies. An unspecific signal was observed in the Calu-3 control lane stained with the CoV-2 N antibody. (B) Flow cytometric analysis of surface ACE2 expression in Calu-3 and iATII cells.
Article Snippet: Proteins were stained at 1:1,000 using
Techniques: Expressing, Western Blot, Infection, Staining, Control
Journal: Cellular and Molecular Life Sciences
Article Title: IFITM1 expression determines extracellular vesicle uptake in colorectal cancer
doi: 10.1007/s00018-021-03949-w
Figure Lengend Snippet: Apc mutation induces Ifitm1 expression in intestinal organoids. A Expression analysis of the TCGA dataset in the Oncomine database ( http://www.oncomine.org ) for the indicated probes. B Relative RNA levels of the indicated genes in wild type (WT) and Apc mutant mouse small intestinal organoids (RT-qPCR, n = 4). C Relative RNA levels of Ifitm1 and the Wnt target gene Prox1 in the indicated mouse small intestinal organoids (RT-qPCR, n = 4). D AXIN2, LGR5, MYC, IFITM1 RNA levels in organoids derived from wild type (WT), adenoma and CRC patients (RT-qPCR, n = 2 for adenoma, n = 3 for normal and CRC samples). E Difference in the expression levels between Lgr5 high and Lgr5 low mouse adenoma cells (bioinformatical analysis of the GSE83513 dataset with the GEO2R online tool). F Comparing the expression levels of LGR5, CD44 , CD133 and IFITM1 between LGR5 high and LGR5 low cells in CRC patient-derived organoids (GSE83513 dataset). Unpaired t-test ( A , D ), paired t-test ( B , C ) or t-test with Benjamini and Hochberg false discovery rate ( E , F ) were used with *p < 0.05, **p < 0.01, ***p < 0.005, n.s.: p > 0.05
Article Snippet: Single cells produced from CRC organoids (see above) were suspended at 2 × 10 5 cells/mL in 16.4 μL Nucleofector Solution and 3.6 μl Supplement (Amaxa SF Cell Line 4D-Nucleofector X Kit S, Lonza) in the presence of 1 μg IFITM1 CRISPR/Cas9 KO and 1 μg
Techniques: Mutagenesis, Expressing, Quantitative RT-PCR, Derivative Assay
Journal: Cellular and Molecular Life Sciences
Article Title: IFITM1 expression determines extracellular vesicle uptake in colorectal cancer
doi: 10.1007/s00018-021-03949-w
Figure Lengend Snippet: Expression level of IFITM1 in human CRC organoids. A The topology of IFITM1 and binding sites of the N-terminal and C-terminal antibodies. B Flow cytometry with antibodies specific for the N-terminal (N-term) or C-terminal (C-term) parts of IFITM1. Note that samples were either directly labelled or were fixed and permeabilized before labelling. C Whole-mount immunocytochemistry of CRC organoids for IFITM1 with antibodies binding to the N-terminal or C-terminal parts of the protein. Immunostaining was carried out with/without permeabilization (org #1). D , E IFITM1 expression in four CRC organoid lines with the antibody recognizing the C-terminal part of the protein. Representative images ( D ) and the quantification of confocal images ( E ) (whole-mount immunostaining). Scale bars: 50 µm ( C , D )
Article Snippet: Single cells produced from CRC organoids (see above) were suspended at 2 × 10 5 cells/mL in 16.4 μL Nucleofector Solution and 3.6 μl Supplement (Amaxa SF Cell Line 4D-Nucleofector X Kit S, Lonza) in the presence of 1 μg IFITM1 CRISPR/Cas9 KO and 1 μg
Techniques: Expressing, Binding Assay, Flow Cytometry, Immunocytochemistry, Immunostaining
Journal: Cellular and Molecular Life Sciences
Article Title: IFITM1 expression determines extracellular vesicle uptake in colorectal cancer
doi: 10.1007/s00018-021-03949-w
Figure Lengend Snippet: The IFITM1 high CRC cell-derived organoids contain more proliferating cells than IFITM1 low organoids. A The fluorescence sorting strategy for IFITM1 high and IFITM1 low cells and their analysis after sorting with flow cytometry. B IFITM1 protein levels of cells sorted from two CRC organoid lines (capillary-based immunoblotting). Note that actin was used as housekeeping control. C Relative RNA levels of the indicated genes in sorted cells (RT-qPCR, n = 4). D The number of organoids initiated by 20,000 sorted cells on day 7. Each dot represents an individual sorting experiment. E Representative images (left panel) and the diameter of CRC organoids (right panel) derived from IFITM1 low or IFITM1 high sorted cells. F The percentage of KI67+ proliferating cells. Representative images and their quantification from confocal images (whole-mount immunostaining). For E and F , quantifications were carried out from ten images taken from four sorting experiments. Scale bars: 50 µm ( E , F ). Paired t-test ( C ) and Mann–Whitney U-test ( D – F ) were used. ***p < 0.005, n.s.: p > 0.05
Article Snippet: Single cells produced from CRC organoids (see above) were suspended at 2 × 10 5 cells/mL in 16.4 μL Nucleofector Solution and 3.6 μl Supplement (Amaxa SF Cell Line 4D-Nucleofector X Kit S, Lonza) in the presence of 1 μg IFITM1 CRISPR/Cas9 KO and 1 μg
Techniques: Derivative Assay, Fluorescence, Flow Cytometry, Western Blot, Control, Quantitative RT-PCR, Immunostaining, MANN-WHITNEY
Journal: Cellular and Molecular Life Sciences
Article Title: IFITM1 expression determines extracellular vesicle uptake in colorectal cancer
doi: 10.1007/s00018-021-03949-w
Figure Lengend Snippet: The IFITM1 high and IFITM1 low CRC cell-derived organoids do not differ in their EV release. A Relative IFITM1 RNA level of sorted cells (d0) and organoids derived from the sorted cells (d7). The RNA levels (normalized to housekeeping) of IFITM1 low samples were taken as 1 in each experiment (RT-qPCR, n = 4). B Immunostaining for IFITM1 directly after sorting or after culturing in 2D or 3D conditions for the indicated time periods (immunostaining and whole-mount immunostaining, confocal microscope images). C , D The percentage of anti-CD63 or anti-CD81-coated positive beads after incubating them in cell-free medium (Ctr), in IFITM1 low or IFITM1 high organoid-derived supernatants and detected by anti-CD63 or anti-CD81 antibody, respectively (flow cytometry). Representative plots ( C ) and quantification of the data ( D ). Note that data were normalized to cell numbers. E , F Nanoparticle Tracking Analysis (NTA) of the organoid supernatants after ultracentrifugation. Representative NTA images ( E ) and data normalized to cell number ( F ). Scale bars: 50 µm ( B ). Paired t-test ( A ) and Mann–Whitney U tests ( D , F ) were used with **p < 0.01 and n.s.: p > 0.05
Article Snippet: Single cells produced from CRC organoids (see above) were suspended at 2 × 10 5 cells/mL in 16.4 μL Nucleofector Solution and 3.6 μl Supplement (Amaxa SF Cell Line 4D-Nucleofector X Kit S, Lonza) in the presence of 1 μg IFITM1 CRISPR/Cas9 KO and 1 μg
Techniques: Derivative Assay, Quantitative RT-PCR, Immunostaining, Microscopy, Flow Cytometry, MANN-WHITNEY
Journal: Cellular and Molecular Life Sciences
Article Title: IFITM1 expression determines extracellular vesicle uptake in colorectal cancer
doi: 10.1007/s00018-021-03949-w
Figure Lengend Snippet: IFITM1 high cells have a reduced EV uptake ability. A , B Medium EV (mEV) uptake in IFITM1 low and IFITM1 high sorted cells. Representative images (left panels) and their quantification (right panels). Sorted cells were cultured 2D for 3 days and they were treated with mEVs derived from DiI-labelled HT29 CRC cells ( A ) or human colon fibroblasts ( B ). Note that mEVs show red fluorescence and phalloidin was used to visualize cells. Confocal microscope images were taken from two independent experiments. The shown images are optical slices from the inside of the cells. C Distribution of the DiI signal intensity in IFITM1 low and IFITM1 high cells. Cells were treated with mEVs derived from DiI-labelled fibroblasts. Note the shift of the curve between the two cell populations. D The fluorescent red signal of mEVs in IFITM1 low sorted cells, cultured for 3 days in 2D conditions. mEVs were collected from DiI-labelled fibroblasts and samples were treated with saponin or Triton X-100. Note that the EV signal disappears when using Triton X-100. E The sorting of CRC organoid cells pre-treated with DiI labelled fibroblast-derived small EVs (sEV) overnight in 2D cultures. F Relative RNA levels of IFITM1, AXIN2 and MYC in the sorted EV+ and EV negative CRC cells (RT-qPCR, n = 3). RNA levels (normalized to housekeeping) of the EV+ samples were always taken as 1. G Relative RNA of the indicated genes in CRC organoid cells (cultured in 2D conditions) with or without fibroblast-derived sEVs (RT-qPCR, n = 3). H IFITM1 level and EV uptake of CRC organoid-derived cells (flow cytometry) in the presence/absence of fibroblast-derived mEVs. I The relative percentage of IFITM1 high and IFITM1 low cells within cells with mEV (left panel) or sEV (right panel) in four CRC organoid lines (flow cytometry). J EV-DiI red fluorescent signal intensity in IFITM1 −/low and IFITM1 high cells after treatment with mEVs or sEVs derived from fibroblasts (left panel) or HT29 cells (right panel). Four organoid lines were measured once or twice (flow cytometry). K IFITM1 level and the uptake of liposomes labelled with DiO (representative flow cytometry images). L DiO green fluorescent signal intensity within the DiO-liposome+ population (data were collected from four organoid lines in 4–5 experiments). Scale bars: 20 µm ( A – C ). Paired t-tests ( F , G ), t-test ( C ), Mann–Whitney U-test ( A , B , J , L ) were used with *p < 0.05, ***p < 0.005 and n.d.: p > 0.05
Article Snippet: Single cells produced from CRC organoids (see above) were suspended at 2 × 10 5 cells/mL in 16.4 μL Nucleofector Solution and 3.6 μl Supplement (Amaxa SF Cell Line 4D-Nucleofector X Kit S, Lonza) in the presence of 1 μg IFITM1 CRISPR/Cas9 KO and 1 μg
Techniques: Cell Culture, Derivative Assay, Fluorescence, Microscopy, Quantitative RT-PCR, Flow Cytometry, Liposomes, MANN-WHITNEY
Journal: Cellular and Molecular Life Sciences
Article Title: IFITM1 expression determines extracellular vesicle uptake in colorectal cancer
doi: 10.1007/s00018-021-03949-w
Figure Lengend Snippet: Fibroblast-derived EVs induce the proliferation of IFITM1 low CRC cells. A The proportion of IFITM1+ CRC cells in the absence of fibroblast-derived EVs or after adding sEVs or mEVs. B The percentage of IFITM1 low /KI67+ and IFITM1 high /KI67+ cells in CRC organoids after the indicated treatments. C The percentage of KI67+ proliferating cells in IFITM1 high or IFITM1 low CRC cell-derived organoids, treated with fibroblast sEVs or mEVs directly after sorting (whole-mount immunostaining and confocal microscope images). D The proportion of active caspase-3+ apoptotic cells in CRC organoids derived from the indicated cell populations, cultured with or without mEVs or sEVs. Images were taken from three experiments for A , B , C and D . Two-way ANOVA, and Tukey post hoc tests were carried out ( A , B , C , D ) with *p<0.05, **p < 0.01, ***p<0.005 and n.s.: p > 0.05. Note that only the relevant comparisons are shown
Article Snippet: Single cells produced from CRC organoids (see above) were suspended at 2 × 10 5 cells/mL in 16.4 μL Nucleofector Solution and 3.6 μl Supplement (Amaxa SF Cell Line 4D-Nucleofector X Kit S, Lonza) in the presence of 1 μg IFITM1 CRISPR/Cas9 KO and 1 μg
Techniques: Derivative Assay, Immunostaining, Microscopy, Cell Culture
Journal: Cellular and Molecular Life Sciences
Article Title: IFITM1 expression determines extracellular vesicle uptake in colorectal cancer
doi: 10.1007/s00018-021-03949-w
Figure Lengend Snippet: Inactivating IFITM1 results in a higher EV uptake. A Cell surface expression of IFITM1 on CRC organoid cells with (IFITM1 KO ) or without (IFITM1 WT ) CRISPR-based inactivation of the molecule (flow cytometry, Ctr: isotype control from IFITM1 WT cells). Representative histograms (left panel) and their quantification are shown (right panel, n = 4, GeoMean values were analyzed). B Immunostaining of CRC organoids derived from IFITM1 WT or IFITM1 KO cells (confocal microscopic images). C The diameters of IFITM1 WT and IFITM1 KO organoids on day 7 of 3D culturing. D The percentage of CRC cells with labelled EV signal in 2D cultures. Cells were isolated from organoids with the indicated genetic background and they were treated with labelled fibroblast-derived mEVs (evaluation of confocal images from four organoid lines). E The percentage of KI67+ organoid cells in the absence of EVs and in the presence of fibroblast-derived mEVs or sEVs (quantification of confocal microscopic images from four organoid lines). Unpaired t-test ( A ), Mann–Whitney U-test ( C , D ) or Kruskal–Wallis and Dunn tests ( E ) were used. Scale bars: 50 µm ( B ). **p<0.01, ***p<0.005, and n.s.: p>0.05
Article Snippet: Single cells produced from CRC organoids (see above) were suspended at 2 × 10 5 cells/mL in 16.4 μL Nucleofector Solution and 3.6 μl Supplement (Amaxa SF Cell Line 4D-Nucleofector X Kit S, Lonza) in the presence of 1 μg IFITM1 CRISPR/Cas9 KO and 1 μg
Techniques: Expressing, CRISPR, Flow Cytometry, Control, Immunostaining, Derivative Assay, Isolation, MANN-WHITNEY
Journal: Cellular and Molecular Life Sciences
Article Title: IFITM1 expression determines extracellular vesicle uptake in colorectal cancer
doi: 10.1007/s00018-021-03949-w
Figure Lengend Snippet: Differential EV uptake by IFITM1 low and IFITM1 high CRC cells has an important effect on the proliferation intensity
Article Snippet: Single cells produced from CRC organoids (see above) were suspended at 2 × 10 5 cells/mL in 16.4 μL Nucleofector Solution and 3.6 μl Supplement (Amaxa SF Cell Line 4D-Nucleofector X Kit S, Lonza) in the presence of 1 μg IFITM1 CRISPR/Cas9 KO and 1 μg
Techniques: